BGNE250117P165000
- 2.95
- 0.000.00%
BeiGene Newsroom
Institutions reiterated a "Buy" rating for BEIGENE (06160), being bullish on its strong oncology drug research and development pipeline.
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (BGNE) Gets a Buy From TD Cowen
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $286
Morgan Stanley Reaffirms Their Buy Rating on BeiGene (BGNE)
BeiGene Analyst Ratings
Morgan Stanley Assumes BeiGene at Overweight, Announces Price Target of $300
Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
Research Reports Prospecting丨China Merchants Securities: First gives Beigene a "strong buy" rating, bullish on the rapid increase in sales of products such as Zejula in the short to medium term.
Research reports highlight | Soochow Securities: Beigene's growth certainty is relatively high, maintaining a "buy" rating.
bocom intl: raised beigene (06160) target price to 159 Hong Kong dollars. Q3 product sales and operation continue to improve.
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Research reports Focus丨Tianfeng: Beigene Q3 adjusted operating profit reached $65.6 million, maintaining a "buy" rating
BeiGene Is Maintained at Buy by TD Cowen